Valuation: Armata Pharmaceuticals, Inc.

Market Cap 121M 108M 99.55M 90.2M 169M 11.47B 172M 1.19B 477M 6.04B 454M 444M 19.03B P/E 2026 *
-1.74x
P/E 2027 * -2.25x
Enterprise Value 121M 108M 99.55M 90.2M 169M 11.47B 172M 1.19B 477M 6.04B 454M 444M 19.03B EV / Sales 2026 *
28.4x
EV / Sales 2027 * 43.9x
Free-Float
32.36%
Yield 2026 *
-
Yield 2027 * -
1 day-1.69%
1 week-11.68%
Current month-12.40%
1 month-12.40%
3 months-32.74%
6 months-67.79%
Current year-48.81%
1 week 3.15
Extreme 3.15
3.84
1 month 2.74
Extreme 2.745
4.07
Current year 2.74
Extreme 2.745
14.98
1 year 2.74
Extreme 2.745
14.98
3 years 0.9
Extreme 0.8981
16.34
5 years 0.83
Extreme 0.8311
16.34
10 years 0.83
Extreme 0.8311
16.34
Manager TitleAgeSince
Chief Executive Officer 70 11/07/2023
Director of Finance/CFO 42 16/08/2024
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 62 09/05/2019
Director/Board Member 66 12/02/2020
Director/Board Member 51 12/02/2020
Date Insider Type Main position Quantity % Market Cap. Importance
10/7/26 Tax

Chief Executive Officer

-14,041 0.0382%
24/4/26 Free

Director

51,280 0.1400%
14/3/26 Tax

Public Communications Manager

1,030 0.0028%
Change 5-day change 1-year change 3-year change Capi.($)
-0.92%-11.68%-35.18%+41.63% 121M
-0.62%+0.50%+33.92%+60.07% 64.38B
+0.35%+3.20%+14.92%+84.55% 56.16B
+0.53%+1.96%+15.37%+106.81% 54.16B
-3.23%-5.01%+22.59%+49.79% 45.33B
-0.73%-2.09%+19.96%+98.13% 42.25B
+0.47%+1.72%+223.08%+936.51% 40.78B
+3.27%+47.96%+112.67%+96.48% 33.8B
+1.22%-1.39%+13.92%+46.95% 32.25B
-1.29%-1.72%+21.00%-6.85% 23.57B
Average -0.17%+3.67%+44.22%+151.41% 39.28B
Weighted average by Cap. -0.08%+3.64%+49.81%+161.95%

Financials

2026 *2027 *
Net sales 4.25M 3.81M 3.5M 3.17M 5.93M 404M 6.04M 41.75M 16.76M 212M 15.95M 15.61M 669M 2.75M 2.46M 2.27M 2.05M 3.84M 261M 3.91M 27.02M 10.85M 137M 10.32M 10.1M 433M
Net income -76.6M -68.6M -63.1M -57.18M -107M -7.27B -109M -753M -302M -3.83B -287M -281M -12.07B -72M -64.48M -59.31M -53.74M -100M -6.84B -102M -707M -284M -3.6B -270M -264M -11.34B
Net Debt - -
Projected Income Statement - Annual - Armata Pharmaceuticals, Inc.
Logo Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.
Employees
61
Date Price Change Volume
31/10/26 US$3.215 -1.08% 26,306
29/10/26 US$3.250 -1.22% 102,950
28/10/26 US$3.290 -5.73% 62,135
27/10/26 US$3.490 +1.16% 104,310
26/10/26 US$3.450 -5.22% 63,646
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Armata Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.250USD
Average target price
17.50USD
Spread / Average Target
+438.46%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Armata Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. ARMP Stock